[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Facciotti, 2022 - Google Patents

Modulation of intestinal immune cell responses by eubiotic or dysbiotic microbiota in inflammatory bowel diseases

Facciotti, 2022

Document ID
12833257176663043650
Author
Facciotti F
Publication year
Publication venue
PharmaNutrition

External Links

Snippet

Background Alterations of the gut microbiota have been linked to aberrant mucosal immune responses, leading to different intestinal and extraintestinal disorders, including inflammatory bowel diseases (IBD) in genetically susceptible hosts. Thus, restoration of …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00—Cosmetic or similar toilet preparations
    • A61K8/18—Cosmetic or similar toilet preparations characterised by the composition
    • A61K8/96—Cosmetic or similar toilet preparations characterised by the composition containing material, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetic or similar toilet preparations characterised by the composition containing material, or derivatives thereof of undetermined constitution from micro-organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens

Similar Documents

Publication Publication Date Title
Sorbara et al. Microbiome-based therapeutics
Anjana et al. Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota
ES2969690T3 (en) Lactobacillus casei or Lactobacillus paracasei for use in the treatment of Clostridium difficile infections
Yadav et al. Microbiome therapeutics: exploring the present scenario and challenges
Hart et al. Use of probiotics in the treatment of inflammatory bowel disease
Toscano et al. A consumer’s guide for probiotics: 10 golden rules for a correct use
Otte et al. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms
Scaldaferri et al. Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility
Buffie et al. Microbiota-mediated colonization resistance against intestinal pathogens
Pace et al. Probiotics in digestive diseases: focus on Lactobacillus GG.
Ceapa et al. Influence of fermented milk products, prebiotics and probiotics on microbiota composition and health
Thomas et al. Probiotics-host communication: modulation of signaling pathways in the intestine
Doron et al. Probiotics: their role in the treatment and prevention of disease
Ng et al. Mechanisms of action of probiotics: recent advances
Rupa et al. Recent advances in the role of probiotics in human inflammation and gut health
JP2019517828A (en) Treatment of Clostridium difficile infection
Golić et al. In vitro and in vivo antagonistic activity of new probiotic culture against Clostridium difficile and Clostridium perfringens
Lim et al. A mixture of the probiotic strains Bifidobacterium longum CH57 and Lactobacillus brevis CH23 ameliorates colitis in mice by inhibiting macrophage activation and restoring the Th17/Treg balance
JP2017515799A (en) Lactobacillus plantarum Inducia strain DSM 21379 as an antimicrobial agent against cholesterol lowering agents and Clostridium difficile
Simpson et al. IBD: microbiota manipulation through diet and modified bacteria
Huang et al. Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022
Salvadori et al. Microbiota, renal disease and renal transplantation
US20220378855A1 (en) Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
Hickson Examining the evidence for the use of probiotics in clinical practice
Xia et al. Effect of Lactobacillus plantarum LP‐Onlly on gut flora and colitis in interleukin‐10 knockout mice